Testing higher-dose proton therapy with chemotherapy for lung cancer
Tests higher-dose proton radiation with chemotherapy in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: IMPT Dose Escalation for NSCLC (HyDose)
Key facts
- Where
- Groningen, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small-cell lung cancer who will get chemotherapy together with radiotherapy, followed by immunotherapy. It tests a higher proton therapy dose to the tumour.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stage III non-small-cell lung cancer (NSCLC), proven by tissue examination. At least 60% of the main tumour must lie outside the mediastinal PRV (the central chest area plus 5 mm).
- Earlier treatment
- Doctors must plan chemotherapy given together with radiotherapy, then immunotherapy afterwards. WHO performance score must be 0-2.
Main reasons for not taking part
- Chemotherapy not given at the same time as radiotherapy
- Immunotherapy afterwards decided to be not possible
- Main tumour overlapping 40% or more with the mediastinal PRV
- Unable or unwilling to understand trial information, give consent or fill out quality-of-life questionnaires
Read by machine on 12 November 2026.
Where in Netherlands
- UMCGGroningen, NetherlandsContact: A. Hessels, MD PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT06484491
- Record updated
- 30 January 2026
- Original description
The goal of this clinical pilot trial is to learn if dose to the tumor in the lung can be safely increased using proton therapy in stage III non-small-cell lung cancer patients receiving combined chemotherapy and radiotherapy. The main questions it aims to answer are:Read full original descriptionShow less
Radiotherapy Dose Escalation Using Intensity-modulated Proton Therapy for Non-small-cell Lung Cancer Patients
The goal of this clinical pilot trial is to learn if dose to the tumor in the lung can be safely increased using proton therapy in stage III non-small-cell lung cancer patients receiving combined chemotherapy and radiotherapy. The main questions it aims to answer are:
* Is the risk of severe radiotherapy toxicities (requiring hospital admission) within acceptable margins ? * What is a rough estimate of the effect of the treatment under study?
Compared to standard care in our clinic, all participants in this pilot trial will
* Receive a higher dose of proton therapy to the tumor in the lung albeit with the same number of radiotherapy visits as the current standard treatment. * Receive two additional follow-up visits at the clinic after treatment, namely 4 and 6 weeks after finishing radiotherapy. * Two additional blood withdrawals at the last week of radiotherapy and 4 weeks after finishing radiotherapy, to measure a type of white blood cells. * Receive an extra quality of life questionnaire at the last week of radiotherapy.
Inclusion: Age ≥18 years; WHO performance score 0-2; Histologically proven stage III NSCLC; Planned for CCRT and adjuvant immunotherapy (intention to treat); Primary tumour volume outside of mediastinal PRV (i.e., mediastinal envelope + 5 mm) ≥60% of total primary tumour volume (true for 75% of patients in preliminary analysis), for sufficient dose escalation.
Exclusion: Chemotherapy not given concurrently with radiotherapy; Upfront decision that adjuvant immunotherapy is not possible; Primary tumour overlapping ≥40% with mediastinal PRV; Unable or unwilling to understand the information on trial-related topics, to give informed consent or to fill out quality-of-life questionnaires.